EverBridge group reached a distribution cooperation with Kaneka group to accelerate i-ED's expansion in China

February 20, 2025 -EverBridge group and Kaneka Medix Corporation (“Kaneka”or “Kaneka group” ) announced that they have reached a distribution cooperation for Kaneka Group's i-ED embolization coils.

According to the terms of the agreement, EverBridge will become the distributor of Kaneka Group's i-ED embolization coils in the Greater China Region, responsible for the sales and promotion of the product in this region (excluding Hong Kong, Macao, Taiwan, Shanghai, Guangdong, Zhejiang, Sichuan, Tianjin and Yunnan).

Intracranial aneurysms are common lesions of hemorrhagic cerebrovascular diseases. If an aneurysm ruptures and bleeds, the patient will experience increased intracranial pressure and edema, and may even induce brain herniation, which will have a serious impact on the respiratory and circulatory centers and lead to death. At present, intracranial aneurysms are mainly treated with neuro-interventional treatments such as coil embolization and flow diverter implantation to prevent intracranial aneurysm rupture or re-bleeding. The i-ED embolization coil developed byKaneka Group has been used in Japan for nearly two decades. It has multiple patented design features: including Wave-SR sutures, PVA detachment zone design and low memory shape, which distinguish the i-ED coil from other coils on the market.

This strategic collaboration represents a pivotal initiative in EverBridge Group's neuroscience business division development plan. By establishing a synergistic partnership with the Kaneka Group, EverBridge has achieved a comprehensive enhancement of its neuroscience product portfolio. The diversified product matrix and expanded market coverage will significantly elevate the business unit's competitive positioning in global markets. This strategic alignment not only reinforces EverBridge's leadership in neurological therapeutics innovation, but also enables it to deliver enhanced therapeutic value to patients worldwide through optimized product availability and clinical outcomes.